Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.58 |
| ▸ | TSHR | P16473 | 5/20 | 0.58 |
| ▸ | USP2 | O75604 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31230966 | 0.98 | CYP2D6 (0.59) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL31230946 | 0.96 | CYP2D6 (0.61) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL24798656 | 0.85 | CYP2D6 (0.68) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL24798927 | 0.85 | CYP2D6 (0.68) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL4875408 | 0.85 | CYP2D6 (0.76) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL5243003 | 0.84 | CYP2D6 (0.67) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL31230967 | 0.83 | CYP2D6 (0.55) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL6749044 | 0.82 | CYP2D6 (0.57) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| Hydrochloric Acid SCHEMBL31717590 | 0.82 | CYP2D6 (0.72) | CYP2D6MEN1KMT2ACYP3A4TSHR | |
| SCHEMBL18712904 | 0.82 | CYP2D6 (0.66) | CYP2D6MEN1KMT2ACYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | TARGACEPT, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7754708-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | BHATTI BALWINDER | 2008-10-02 | — | — | US | disclosed |
| US-7384929-B2 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | TARGACEPT, INC. (US) | 2008-06-10 | — | — | US | disclosed |
| EP-1802601-A1 | AZASPIROALKENE AND AZAPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | Targacept, Inc. (US) | 2007-07-04 | — | — | EP | disclosed |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | BHATTI BALWINDER | 2006-04-06 | — | — | US | disclosed |
| WO-2006034089-A1 | AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS WITH NICOTINIC CHOLINERGIC RECEPTOR ACTIVITY | TARGACEPT, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240689-A1 | N-ARYL AZASPIROALKENE AND AZASPIROALKANE COMPOUNDS AND METHODS OF PREPARATION AND USE THEREOF | MUSK, TNNC1, CHRNA5 | CYP2D6 74/4885MEN1 4523/4885KMT2A 2681/4885 |
| US-20060074067-A1 | N-aryl azaspiroalkene and azaspiroalkane compounds and methods of preparation and use thereof | MUSK, TNNC1, CHRNA5 | CYP2D6 74/4885MEN1 4523/4885KMT2A 2681/4885 |
| US-20080242689-A1 | Analgesics, central nervous system disorders, obesity, side effect reduction | OPRL1, OPRK1, ACHE | CYP2D6 42/4885MEN1 4626/4885KMT2A 2574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.